×

Cerevance – CVN766

Cerevance is a drug discovery company advancing treatments for brain diseases. The company’s lead program, Cerevance has 5 compounds under development.. The aim of development for CVN766 is to treat psychiatric disorders including negaive and cognitive symptoms of schizophrenia. Craig Thompson is the current CEO.

Organizations:

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2025 Lifespan Research Institute – ALL RIGHTS RESERVED